Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer

Cancer Research

Volumn 66, Issue 1, 2006, Pages 175-183

  You, Zongbing ^a   Shi, Xu Bao ^b   DuRaine, Grayson ^a   Haudenschild, Dominik ^a   Tepper, Clifford G ^a   Lo, Su Hao ^a   Gandour Edwards, Regina ^a   De Vere White, Ralph W ^b   Reddi, A Hari ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 2; CASPASE 3; CASPASE 8; CYTOKINE RECEPTOR; INTERLEUKIN 17 RECEPTOR LIKE PROTEIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANDROGEN RELEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; IL 17RL GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR GENE; TUMOR GROWTH; XENOGRAFT;

ANIMALS; APOPTOSIS; CASPASES; CELL ADHESION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMANS; ISOENZYMES; MALE; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 31544471398     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1130     Document Type: Article

References (50)

1. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA 1991;265:618-21.
2. Roudier MP, True LD, Higano CS, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34:646-53.
3. De La Taille A, Vacherot F, Salomon L, et al. Hormone-refractory prostate cancer: a multi-step and multi-event process. Prostate Cancer Prostatic Dis 2001;4:204-12.
4. Craft N, Sawyers CL. Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metastasis Rev 1999;17:421-7.
5. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45:586-92; discussion 592.
6. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52: 6940-4.
7. Cleave M, Jansen B. Clusterin and IGFBPs as antisense targets in prostate cancer. Ann N Y Acad Sci 2003;1002: 95-104.
8. Nesslinger NJ, Shi XB, deVere White RW. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res 2003;63:2228-33.
9. Abate-Shen C, Banach-Petrosky WA, Sun X, et al. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 2003;63:3886-90.
10. Graff JR, Konicek BW, McNulty AM, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kipl expression. J Biol Chem 2000;275: 24500-5.
11. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004;21:467-76.
12. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003;14:155-74.
13. Shi Y, Ullrich SJ, Zhang J, et al. A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem 2000;275:19167-76.
14. Lee J, Ho WH, Maraoka M, et al. IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rhl. J Biol Chem 2001:276:1660-4.
15. Furthauer M, Lin W, Ang SL, Thisse B, Thisse C. Sef is a feedback-induced antagonist of Ras/MAPK-mediated FGF signalling. Nat Cell Biol 2002;4:170-4.
16. Tsang M, Friesel R, Kudoh T, Dawid IB. Identification of Sef, a novel modulator of FGF signalling. Nat Cell Biol 2002;4:165-9.
17. Witowski J, Ksiazek K, Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci 2004;61:567-79.
18. Tartour E, Fossiez F, Joyeux I, et al Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999; 59:3698-704.
19. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101:2620-7.
20. Hirahara N, Nio Y, Sasaki S, et al. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology 2001;61:79-89.
21. Benchetrit F, Ciree A, Vives V, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002;99:2114-21.
22. Steiner GE, Newman ME, Paikl D, et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003;56:171-82.
23. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607-16.
24. Haudenschild D, Moseley T, Rose L, Reddi AH. Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J Biol Chem 2002;277:4309-16.
25. Shi XB, Ma AH, Tepper CG, et al. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 2004;60:257-71.
26. Lee MS, Garkovenko E, Yun JS, et al. Characterization of adult human prostatic epithelial cells immortalized by polybrene-induced DNA transfection with a plasmid containing an origin-defective SV40 genome. Int J Oncol 1994;4:821-30.
27. You Z, DuRaine G, Tien JYL, Lee C, Moseley TA, Reddi AH. Expression of interleukin-17B in mouse embryonic limb buds and regulation by BMP-7 and bFGF. Biochem Biophys Res Commun 2005;326:624-31.
28. You Z, Saims D, Chen S, et al. Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol 2002;157:429-40.
29. Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, deVere White RW. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 1998;83:2534-9.
30. Akiyama SK. Functional analysis of cell adhesion: quantitation of cell-matrix attachment. In: Adams J, editor. Methods in cell biology. Vol. 69. San Diego: Academic Press; 2002. p. 281-96.
31. Wainstein MA, He F, Robinson D, et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994;54:6049-52.
32. Nagabhushan M, Miller CM, Pretlow TP, et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56:3042-6.
33. Chopra DP, Menard RE, Januszewski J, Mattingly RR. TNF-α-mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. Cancer Lett 2004;203:145-54.
34. Pretlow TG, Wolman SR, Micale MA, et al. Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 1993;85:394-8.
35. Tepper CG, Boucher DL, Ryan PE, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002;62:6606-14.
36. Lin J, Adam RM, Santiestevan E, Freeman MR The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999;59: 2891-7.
37. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3:737-47.
38. Jiang X, Wang X. Cytochrome c -mediated apoptosis. Annu Rev Biochem 2004;73:87-106.
39. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem 2000;69:217-45.
40. Khosravi-Far R, Esposti MD. Death receptor signals to mitochondria. Cancer Biol Ther 2004;3:1051-7.
41. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-3.
42. Ittmann MM. Chromosome 10 alterations in prostate adenocarcinoma [review]. Oncol Rep 1998;5:1329-35.
43. You Z, Ouyang H, Lopatin D, Polver PJ, Wang CY. Nuclear factor-κ B-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity. J Biol Chem 2001;276:26398-404.
44. You Z, Madrid LV, Saims D, Sedivy J, Wang CY. c-Myc sensitizes cells to tumor necrosis factor-mediated apoptosis by inhibiting nuclear factor κ B transactivation. J Biol Chem 2002;277:36671-7.
45. van der Flier A, Sonnenberg A. Function and interactions of integrals. Cell Tissue Res 2001;305:285-98.
46. Fukuda T, Guo L, Shi X, Wu C. CH-ILKBP regulates cell survival by facilitating the membrane translocation of protein kinase B/Akt. J Cell Biol 2003;160:1001-8.
47. Meredith JE, Jr., Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993;4:953-61.
48. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001;13:555-62.
49. Lee JW, Juliano RL. The α5β1 integrin selectively enhances epidermal growth factor signaling to the phosphatidylinositol-3-kinase/Akt pathway in intestinal epithelial cells. Biochim Biophys Acta 2002;1542:23-31.
50. Miranti CK, Brugge JS. Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol 2002;4:E83-90.